10-K: Avidity Biosciences Secures \$40 Million Investment from Bristol Myers Squibb in Expanded Collaboration

Avidity Biosciences has entered into a strategic collaboration with Bristol Myers Squibb, including a \$40 million equity investment, to advance cardiovascular therapeutics using its AOC platform.

Summary

• Avidity Biosciences has entered into a research collaboration and license agreement with Bristol Myers Squibb (BMS), which includes a \$40 million equity investment by BMS.
• The collaboration focuses on the discovery, development, and commercialization of up to five cardiovascular targets using Avidity's Antibody Oligonucleotide Conjugate (AOC) platform.
• BMS will pay Avidity \$100 million upfront, which includes the \$40 million equity investment, and Avidity is eligible for up to approximately \$2.2 billion in milestone payments, plus tiered royalties on net sales.
• Avidity will be responsible for its own research collaboration costs up to a cumulative spending limit of \$40 million, while BMS will fund all future clinical development, regulatory, and commercialization activities.
• The agreement also includes a lock-up period for BMS, restricting the sale of shares until May 25, 2024, with certain exceptions for strategic transactions.
• The agreement outlines the purchase and sale of shares, closing conditions, representations and warranties of both parties, registration rights, and other agreements.
• The agreement also includes details about indemnification, prospectus suspension, termination of obligations, and reporting requirements.

Sentiment

Score: 8

Explanation: The document reflects a positive development for Avidity Biosciences, with a significant investment and collaboration agreement. The potential for future revenue and the validation of their technology contribute to a strong positive sentiment.

Positives

• The collaboration with BMS provides significant upfront funding and potential future revenue through milestone payments and royalties.
• The equity investment from BMS validates Avidity's technology and potential in the cardiovascular space.
• The agreement allows Avidity to leverage BMS's expertise in clinical development and commercialization.
• The lock-up period for BMS shares provides stability and reduces the risk of immediate stock dilution.

Negatives

• Avidity is responsible for its own research collaboration costs up to a cumulative spending limit of \$40 million.
• The agreement includes a lock-up period for Avidity, restricting the sale of shares until May 25, 2024, with certain exceptions for strategic transactions.

Risks

• The success of the collaboration depends on the successful development and commercialization of the cardiovascular targets.
• There is a risk that milestone payments may not be achieved, and royalties may not be significant.
• The lock-up period for BMS shares could limit their ability to sell shares if needed.
• The agreement includes a lock-up period for Avidity, restricting the sale of shares until May 25, 2024, with certain exceptions for strategic transactions.

Future Outlook

The document outlines a strategic collaboration with potential for significant future revenue through milestone payments and royalties, contingent on the successful development and commercialization of cardiovascular therapeutics.

Management Comments

• The document does not contain any direct quotes from management, but it does outline the terms of the agreement between the two companies.

Industry Context

This collaboration reflects a growing trend in the biopharmaceutical industry where companies are partnering to leverage each other's strengths in drug discovery and development. It also highlights the increasing interest in RNA therapeutics and their potential to address a wide range of diseases.

Comparison to Industry Standards

• The structure of this collaboration, including upfront payments, milestone payments, and royalties, is consistent with industry standards for licensing and research agreements.
• The equity investment by BMS is a strong signal of confidence in Avidity's technology and potential.
• The size of the potential milestone payments (up to \$2.2 billion) is significant and reflects the high value placed on successful drug development in the cardiovascular space.
• The tiered royalty structure is also typical of such agreements, providing Avidity with a share of future sales revenue.

Related Party Transactions

• The agreement outlines a related party transaction between Avidity and BMS, with BMS purchasing shares of Avidity's common stock.

Stakeholder Impact

• Shareholders: The agreement is likely to positively impact the share price of Avidity Biosciences due to the investment and potential future revenue.
• Employees: The collaboration may lead to increased job security and opportunities for growth within Avidity.
• Customers: The collaboration may lead to the development of new and improved cardiovascular therapeutics.
• Suppliers: The agreement may lead to increased demand for Avidity's services and products.
• Creditors: The agreement may improve Avidity's financial stability and ability to meet its obligations.

Next Steps

• Avidity will continue to conduct research and development activities under the collaboration agreement.
• BMS will begin clinical development, regulatory, and commercialization activities for the cardiovascular targets.
• Avidity will file a Resale Registration Statement to register the shares sold to BMS.
• The Parties will work together to achieve the milestones outlined in the agreement.

Key Dates

Keywords

Avidity Biosciences, Bristol Myers Squibb, AOC platform, cardiovascular therapeutics, research collaboration, equity investment, milestone payments, royalties, lock-up period, securities purchase agreement